Clinical Epidemiology 2016 October [Link] Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, Gadgeel S Abstract INTRODUCTION: Mesothelioma is a rare malignancy typically associated with exposure to asbestos and poor survival. The purpose of this investigation was to describe mesothelioma patient characteristics, treatment patterns, and overall survival (OS) utilizing the National…

Read More

Journal of Clinical Oncology: Official journal of the American Society of Clinical Oncology 2016 June 20 [Epub ahead of print] [Link] Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LM. Abstract PURPOSE: We conducted…

Read More

International Journal of Cancer 2016 June 10 [Epub ahead of print] [Link] Kuryk L, Haavisto E, Garofalo M, Capasso C, Hirvinen M, Pesonen S, Ranki T, Vassilev L, Cerullo V. Abstract Malignant mesothelioma (MM) is a rare cancer type caused mainly by asbestos exposure. The median overall survival time of a mesothelioma cancer patient is…

Read More

Medical Oncology 2015 February [Link] de Lima VA, Sorensen JB. Abstract There is no well-defined standard third-line chemotherapy for advanced malignant pleural mesothelioma (MPM). However, combination of carboplatin, liposomised doxorubicin (Caelyx) and gemcitabine (CCG regimen) has revealed noteworthy activity when used as first-line treatment. The aim of this study is to assess efficacy and toxicity…

Read More

Annals Italiani di Chirurgia 2014 November [Link] Valerio S, Bracale UM, Giribono AM, Viviani E, Caioni F, Del Guercio L. Abstract Pemetrexed and Carboplatin are two well-known chemioterapic agents used for the treatment of many tumors, especially for lung cancer and mesothelioma. Peripheral ischemic events related to Pemetrexed and Carboplatin are rarely reported. We herein…

Read More

Annali Italiani di Chirurgia 2014 November [Link] Valerio S, Bracale UM, Giribono AM, Viviani E, Caioni F, Del Guercio L. Abstract Pemetrexed and Carboplatin are two well-known chemioterapic agents used for the treatment of many tumors, especially for lung cancer and mesothelioma. Peripheral ischemic events related to Pemetrexed and Carboplatin are rarely reported. We herein…

Read More

Anticancer Research. 2012 Dec;32(12):5393-9. [Link] Pasello G, Marulli G, Polo V, Breda C, Bonanno L, Loreggian L, Rea F, Favaretto A. Via Gattamelata 64, 35128, Padua, Italy. giulia.pasello@ioveneto.it. Abstract Aim: The objective of this study was the retrospective evaluation of tolerability and activity of pemetrexed with carboplatin (AC) or cisplatin (AP) as neoadjuvant chemotherapy in…

Read More

Clinical Cancer Research. 2011 Apr 15;17(8):2581-90. Epub 2011 Jan 24. [Link] Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A. Department of Oncology, Biostatistics Unit, Istituto Clinico Humanitas IRCCS,…

Read More

Lung Cancer. 2009 May;64(2):211-8. Epub 2008 Nov 29. [Link] Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C, Stahel R. Cardarelli Hospital, Medical Oncology, Via Cardarelli 9, 80100 Naples, Italy. giacomo.carteni@ospedalecardarelli.it Abstract Aim: Peritoneal mesothelioma (PM) has rarely been studied. The Expanded Access Program (EAP) provided…

Read More

Journal of Thoracic Oncology. 2008 Nov;3(11):1325-31. [Link] Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A. Department of Lung Medicine and Allergology, Karolinska University Hospital, Solna, Stockholm, Sweden. gunnar.hillerdal@karolinska.se Abstract Background: Malignant pleural mesothelioma has a poor prognosis and there is limited effect of treatment. The Nordic Mesothelioma groups decided in the…

Read More